Allergy Thera. Regulatory News (AGY)

14 Jul 2006 07:01

Allergy Therapeutics PLC14 July 2006 Allergy Therapeutics plc, "Allergy Therapeutics" or "the Company" Trading update Allergy Therapeutics plc, the specialist pharmaceuticals company focused onallergy vaccination, today issues the following pre-close trading updaterelating to the financial year ended 30 June 2006. The preliminary results for the year will be announced on 12 September 2006.Sales for the year are expected to be approximately £23.5m, in line with currentmarket expectations. Allergy Therapeutics has made excellent progress with its clinical programmesduring the year. These programmes are focused on the development of theCompany's lead product, Pollinex(R) Quattro, an innovative four-shot vaccinationfor allergy sufferers. Allergy Therapeutics is now in an excellent position, having: - one product ready for submission for registration in Canada - Pollinex Quattro Ragweed - one product in Phase III studies worldwide - Pollinex Quattro Grass o Clarity on the crucially important 'route to registration' established - two products at the Phase II/III interface worldwide - Pollinex Quattro Tree and Pollinex Quattro Ragweed - the financial resources to continue the development programme independently - the clinical results to explore options for partnering from a position of strength -ends- Allergy Therapeutics 01903 844720 Keith Carter, Chief Executive Ian Postlethwaite, Finance Director Bell Pottinger 020 7861 3232 Dan de Belder / Emma Charlton This information is provided by RNS The company news service from the London Stock Exchange